Published in Drug Week, September 10th, 2004
"Mid-to late-stage Parkinson's disease is by and large an untreated condition. AV201 has shown considerable promise as a treatment in animal models of Parkinson's disease, and we are excited to be moving this product into the clinic," said Dawn McGuire, MD, Avigen's chief medical officer.
Parkinson disease (PD) is the second most common neurodegenerative disease, affecting an estimated two million individuals in the United States and Europe.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.